Nonalcoholic Steatohepatitis (NASH) Clinical Trials

6 recruitingLast updated: May 13, 2026

There are 6 actively recruiting nonalcoholic steatohepatitis (nash) clinical trials across 30 countries. Studies span Phase 1, Phase 3, Phase 2. Top locations include Amarillo, Texas, United States, Amiens, France, Albuquerque, New Mexico, United States. Updated daily from ClinicalTrials.gov.


Nonalcoholic Steatohepatitis (NASH) Trials at a Glance

6 actively recruiting trials for nonalcoholic steatohepatitis (nash) are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Amarillo, Amiens, and Albuquerque. Lead sponsors running nonalcoholic steatohepatitis (nash) studies include 89bio, Inc., Centre hospitalier de l'Université de Montréal (CHUM), and Changchun Intellicrown Pharmaceutical Co. LTD.

Browse nonalcoholic steatohepatitis (nash) trials by phase

Treatments under study

About Nonalcoholic Steatohepatitis (NASH) Clinical Trials

Looking for clinical trials for Nonalcoholic Steatohepatitis (NASH)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nonalcoholic Steatohepatitis (NASH) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nonalcoholic Steatohepatitis (NASH) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled296 locationsNCT06419374
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 2

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Nonalcoholic Steatohepatitis (NASH)
Polaris Group60 enrolled10 locationsNCT05842512
Recruiting
Phase 1

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)
Changchun Intellicrown Pharmaceutical Co. LTD138 enrolled1 locationNCT06216041
Recruiting

Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Fatty Liver Disease (NAFLD)
Centre hospitalier de l'Université de Montréal (CHUM)102 enrolled1 locationNCT03572465